接受艾比特思和化学疗法联合治疗的222名患者平均幸存了40周。
The 222 patients treated with Erbitux and chemotherapy survived for an average of 40 weeks.
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
但是，他将其和一种名为艾比特思的抗体联合了起来，后者通过与促进癌细胞扩散和生长的蛋白结合来对它进行抑制。
He did, however, combine it with Erbitux, an antibody that binds to and thus disables a protein that promotes the proliferation and growth of cells.
应用推荐